Zhejiang Medicine Collaborates with Ambrx and WuXi on Breast Cancer Drug
publication date: Jun 17, 2013
Zhejiang Medicine Co. formed a collaboration with Ambrx of San Diego to develop an Ambrx molecule that targets Her2-positive breast cancer. Ambrx genetically engineers proteins that contain new amino acids with different properties than those of the 20 natural-occurring amino acids. The company’s technology is centered on antibody-drug conjugates, which combine a targeting agent and a cytotoxic. In return for China rights, Zhejiang will underwrite the costs of development, which will be carried out by WuXi PharmaTech. More details....
Stock Symbols: (SHA: 600216) (NYSE: WX)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.